JOP20200034A1 - تركيبة للتنشيط المتحكم فيه للمبيض - Google Patents

تركيبة للتنشيط المتحكم فيه للمبيض

Info

Publication number
JOP20200034A1
JOP20200034A1 JOP/2020/0034A JOP20200034A JOP20200034A1 JO P20200034 A1 JOP20200034 A1 JO P20200034A1 JO P20200034 A JOP20200034 A JO P20200034A JO P20200034 A1 JOP20200034 A1 JO P20200034A1
Authority
JO
Jordan
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
fsh
Prior art date
Application number
JOP/2020/0034A
Other languages
English (en)
Inventor
Saez Joan-Carles Arce
Bjarke Mirner Klein
Lisbeth Helmgaard
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of JOP20200034A1 publication Critical patent/JOP20200034A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOP/2020/0034A 2017-09-01 2018-08-31 تركيبة للتنشيط المتحكم فيه للمبيض JOP20200034A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
JOP20200034A1 true JOP20200034A1 (ar) 2020-02-13

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0034A JOP20200034A1 (ar) 2017-09-01 2018-08-31 تركيبة للتنشيط المتحكم فيه للمبيض

Country Status (31)

Country Link
US (2) US11744879B2 (ar)
EP (3) EP3973982B1 (ar)
JP (2) JP6856819B2 (ar)
KR (1) KR20200045543A (ar)
CN (1) CN111050787A (ar)
AR (1) AR112541A1 (ar)
AU (1) AU2018326556B2 (ar)
BR (1) BR112020003379A2 (ar)
CA (1) CA3073624A1 (ar)
CL (1) CL2020000482A1 (ar)
DK (2) DK3675894T3 (ar)
EA (1) EA202090480A1 (ar)
ES (1) ES2904787T3 (ar)
FI (1) FI3973982T3 (ar)
HR (1) HRP20211802T1 (ar)
HU (1) HUE056726T2 (ar)
IL (1) IL272763B2 (ar)
JO (1) JOP20200034A1 (ar)
LT (2) LT3973982T (ar)
MA (2) MA56224A (ar)
MD (1) MD3675894T2 (ar)
MX (2) MX2020002235A (ar)
PH (1) PH12020500404A1 (ar)
PL (1) PL3675894T3 (ar)
PT (2) PT3973982T (ar)
RS (1) RS62810B1 (ar)
SG (1) SG11202003840QA (ar)
SI (1) SI3675894T1 (ar)
TW (1) TWI749255B (ar)
UA (1) UA126869C2 (ar)
WO (1) WO2019043143A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442748A1 (en) * 2000-01-27 2004-08-04 Applied Research Systems ARS Holding N.V. Use of FSH for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2009036771A1 (es) * 2007-09-21 2009-03-26 Pharmabrand S.A. Composición de polisacáridos mucilaginosos, derivados de aloe barbadensis, en combinación con liposomas, procedimiento de obtención y uso de la misma como fotoprotectora, antiacné, regeneradora de la epidermis e hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
PL2621517T5 (pl) 2010-09-29 2024-01-29 Ferring B.V. Kompozycja do stosowania w leczeniu niepłodności
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
KR20160144480A (ko) * 2014-04-18 2016-12-16 글리코토페 게엠베하 개선된 재조합 인간 난포-자극 호르몬을 이용한 조절된 난소 과다자극
JP7163027B2 (ja) 2015-02-26 2022-10-31 フェリング ベスローテン フェンノートシャップ 不妊症の処置方法
EP3662925B1 (en) * 2015-04-17 2021-04-07 Ferring B.V. Composition comprising fsh for treatment of infertility
JP6964519B2 (ja) 2015-04-24 2021-11-10 フェリング ベスローテン フェンノートシャップ ゴナドトロピンの製造方法
CN107709350A (zh) 2015-06-26 2018-02-16 辉凌公司 纯化和/或病毒灭活的方法
CN112088011A (zh) 2018-04-30 2020-12-15 辉凌公司 用于受控的卵巢刺激的组合物
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
EP3675894B1 (en) 2021-11-03
MX2024009224A (es) 2024-08-06
DK3675894T3 (da) 2022-01-24
MA50034B1 (fr) 2022-02-28
US20240024424A1 (en) 2024-01-25
PT3973982T (pt) 2024-09-16
BR112020003379A2 (pt) 2020-08-25
IL272763B2 (en) 2024-02-01
SG11202003840QA (en) 2020-05-28
EP3675894A1 (en) 2020-07-08
FI3973982T3 (fi) 2024-09-23
LT3973982T (lt) 2024-09-10
MX2020002235A (es) 2020-07-20
CA3073624A1 (en) 2019-03-07
JP2021046398A (ja) 2021-03-25
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
TWI749255B (zh) 2021-12-11
US20200197493A1 (en) 2020-06-25
PT3675894T (pt) 2022-01-25
WO2019043143A1 (en) 2019-03-07
DK3973982T3 (da) 2024-09-23
EP3973982A1 (en) 2022-03-30
HUE056726T2 (hu) 2022-03-28
MD3675894T2 (ro) 2022-03-31
MA50034A (fr) 2021-05-12
ES2904787T3 (es) 2022-04-06
EP4427806A2 (en) 2024-09-11
EP3973982B1 (en) 2024-07-31
IL272763A (en) 2020-04-30
CN111050787A (zh) 2020-04-21
PH12020500404A1 (en) 2021-03-01
HRP20211802T1 (hr) 2022-03-04
JP6856819B2 (ja) 2021-04-14
UA126869C2 (uk) 2023-02-15
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
MA56224A (fr) 2022-04-20
AU2018326556B2 (en) 2024-09-26
US11744879B2 (en) 2023-09-05
KR20200045543A (ko) 2020-05-04
TW201919687A (zh) 2019-06-01
RS62810B1 (sr) 2022-02-28
JP2020528071A (ja) 2020-09-17
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
JP7373479B2 (ja) 2023-11-02
CL2020000482A1 (es) 2020-06-26
AU2018326556A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2014001489A (es) Composicion para la estimulacion ovarica controlada.
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
PH12017501300A1 (en) Novel iodophor composition and methods of use
NZ745186A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
MX2020000402A (es) Nuevos derivados de xantina sustituidos.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2018002921A (es) Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
NZ762312A (en) Anti-pacap antibody
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12020500404A1 (en) Composition for controlled ovarian stimulation
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2017013879A (es) Composiciones que comprenden anakinra.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.